Phase 1 Trial of Investigational BT-11 Begins Dosing First Volunteers, Landos Announces

Phase 1 Trial of Investigational BT-11 Begins Dosing First Volunteers, Landos Announces
A Phase 1 clinical trial testing Landos Biopharma’s investigational therapy BT-11 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), has begun dosing healthy volunteers. Landos plans to enroll up to 70 healthy participants in the randomized, double-blind, placebo-controlled Phase 1 trial. They will be assigned to single and multiple ascending doses of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *